ALMR

Image source: The Motley Fool. Monday, Aug. 10, 2026 at 4:30 p.m. ET Vice President of Investor Relations and Corporate Communications - Carrie Mendivil Chief Executive Officer - Yuling Luo Chief Financial Officer - Justin McAnear President - Tod White Operator: Good day, and thank you for standing by. Welcome to the Alamar Biosciences Second Quarter 2026 Financial Results Webcast Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Carrie Mendivil, Vice President of Investor Relations and Corporate Communications. Please proceed. Carrie Mendivil: Good afternoon, everyone, and thank you for joining us today to review Alamar Biosciences' Second Quarter 2026 Financial Results. Joining me on the call are Yuling Luo, our Chief Executive Officer; and Justin McAnear, Chief Financial Officer. Our President, Tod White, will join for Q&A. Earlier this afternoon, we issued a press release detailing our second quarter financial results, and we posted an accompanying presentation in the Investors section of our website. Before we begin, I'd like to remind you that statements we make during this call will include forward-looking statements as defined under applicable securities laws. Forward-looking statements are subject to risks and uncertainties, and the company can give no assurance that they will prove to be correct. Additionally, we are not under any obligation to provide further updates on our business trends or our performance during the quarter. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the periodic reports that Alamar Biosciences files with the Securities and Exchange Commission, including our quarterly report on Form 10-Q filed on May 8, 2026. I will now turn the call over to Yuling Luo, Alamar's CEO. Yuling Luo: Thank you, Carrie, and thank you all for joining us this afternoon for our first earnings call as a public company. Before I begin, I want to thank our investors for their trust and support following our successful initial public offering. On behalf of the entire Alamar team, we remain committed to delivering meaningful impact while creating long-term shareholder value. I will start our call with a brief overview of Alamar and our platform, then walk through our Q2 business highlights and close with our strategy to unlock the opportunity ahead. I will then turn it over to Justin to cover our financials and the revenue outlook for the remainder of the year. Starting on Slide 3. 8 years ago, we founded Alamar with a singular mission: to power precision proteomics for the earliest possible detection of disease. That mission remains our North Star. The proteomics market represents a massive, largely untapped opportunity. We believe the reason it has remained untapped is not because of a lack of demand, but because of lack of sensitive and sophisticated tools. That is the technology gap Alamar was built to close. And today, I believe we are delivering on it. Turning to Slide 4. What sets Alamar apart is simple. We are the only platform to combine all 5 elements essential for [ policiting ] proteomics: ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. Existing technologies have historically demanded a trade-off: a sacrifice in sensitivity, in multiplexing capability or in workflow simplicity. Our platform was specifically designed to eliminate those trade-offs. Since launching our precision proteomics platform in January 2024, adoption has been phenomenal. Starting with our top line results on Slide 5. Q2 2026 was a strong quarter that reflects the momentum of our business. Total revenue grew 82% year-over-year, driven by exceptional consumable performance. Consumable revenue accounted for 53% of our total revenue and was up 147% compared to Q2 2025. For the first time, we also achieved a 60% gross margin. Turning to Slide 6. We are focused on 3 key drivers to sustain and expand adoption of our platform in the near term. First, growing our instrument installed base to reach new institutions and geographies; second, developing novel content to extend our leadership in our beachhead neurology and inflammation research markets and enter adjacent disease areas with significant unmet need; and third, collaborating with leading institutions to develop new applications, support third-party studies and grow our publication base to drive awareness and adoption of our platform. Turning to Slide 7. We're making meaningful progress across each of these areas. We continue to expand our installed base, launching 3 new RUO products that extend the reach and the utility of our platform, deepening our strategic partnership, surpassed 165 cumulative publications and preprints and delivered our strongest scientific presence ever at Alzheimer's Association International Conference. I go through each of these achievements in a bit more detail. Turning to Slide 8. We have built a clear leadership position in neurodegenerative research. In middle March, we launched our new Neuro 220 Panel and have seen incredible adoption. In early July, we launched the first commercial multiplex blood-based immunoassay for eMTBR-tau, which is emerging as one of the most important biomarkers in Alzheimer's disease research. Our eMTBR-tau provides a noninvasive blood-based measurement of tau tangle burden, with attomolar sensitivity multiplexed alongside other neurodegeneration and neuroinflammation biomarkers from a single low-volume sample. We have validated this across multiple cohorts, and we have already seen data being submitted for publication from multiple customer labs. We showcased this data at our workshop at AAIC and the reception was outstanding. It sets the stage for what was our strongest AAIC presence to date. Turning to Slide 9. We came away from AAIC with a strong sense that the field is approaching an inflection point, and Alamar is at the center of it. We counted more than 140 posters and presentations featuring NULISA technology, a fourfold increase year-over-year. Three things from the conference reinforce our conviction in where the market is heading. First, blood-based biomarkers are going mainstream. Second, tau is emerging as a central drug target, with Biogen advancing their tau-lowering drug into Phase III and others following. The timing of our eMTBR-tau launch could not be better positioned. Third, there is a growing appreciation for the complexity of the neurodegenerative disease. Researchers are increasingly focused on heterogeneity and co-pathology, including alpha-synuclein, frontotemporal dementia and vascular disease, driving demand for the kind of deeply multiplexed multi-target panels that only our platform can deliver. Turning to Slide 10. Our leadership position in neurodegenerative disease research is translating into increasing use of our platform in large cohort studies. Today, we announced the expansion of our strategic partnership with the Alzheimer's Disease Data Initiative and Gates Ventures, adding profiling of an additional 86,000 plasma samples using our NULISAseq Neuro 220 Panel. This builds on our June 2025 announcement of a multicenter initiative that profiled over 55,000 samples. Included within this expanded agreement is a national scale initiative co-led by researchers at 3 leading universities to profile approximately 21,000 plasma samples from 10,000 Alzheimer's disease research center participants across the United States. Expected to complete in 2027, the combined data set will encompass more than 140,000 samples profiled across multiple geographies and cohorts made available to the global research community through the Global Neurodegeneration Proteomics Consortium. We believe this partnership will generate one of the most unique resources available today for understanding neurodegenerative disease. Turning to Slide 11. Beyond neurology, we are also expanding content for our other initial market: inflammation. Two weeks ago, we launched our NULISAseq Immune 340 Panel, our broadest multiplex immune profiling panel. It expands on NULISAseq Inflammation Panel 250, our first immune panel. The biology driving this expansion is chronic low-grade inflammation, which is implicated across cancer, cardiovascular, metabolic disease, neurological disease, autoimmune disease and aging. Until now, much of that biology has been out of reach because many immune mediators circulating at concentrations below the detection floor of conventional immunoassay. The Immune 340 Panel addresses that directly with attomolar sensitivity and simultaneous measurement of approximately 340 immune-related proteins from a single blood sample. It captures the regulatory signals, feedback loops and low abundance mediators that other platforms routinely miss. We believe this panel opens a large and underpenetrated market opportunity, and we are replicating in immunology the same playbook that has driven our success in neurodegenerative disease. Turning to Slide 12. We also expanded the capability of our platform with the launch of NULISA Dried Blood Spot Extraction Kit, making home collected fingerstick samples compatible with our ultra-high sensitivity multiplex proteomics platform. Historically, there has been a significant technical challenge to recover protein signals from small volume dried blood spots without losing the low abundance biology researchers care about. Our Dried Blood Spot Extraction Kit delivers the high target detectability across our neurology and inflammation panels using many microsampling platforms. We believe remote at-home sample collection will be the key requirement to power future population scale screening and health monitoring tests. Turning to Slide 13. In Q2, we added more than 40 new publications and preprints, bringing our cumulative total to 165, spanning neurodegenerative disease, oncology, cardiovascular, metabolic and autoimmune conditions. The breadth and depth of this rapidly growing publications really highlight the impact of our platform. A particular compelling example come from Dr. Carlos Cruchaga at the Washington University, highlighted on Slide 14. Published in the Journal of the Alzheimer's Association, the study used our platform to develop an AI-based classifier capable of diagnosing neurodegenerative diseases and categorizing co-pathology from a blood sample. What makes this study particularly striking is that a carefully selected panel of just 15 proteins delivers a strong diagnostic and co-pathology classification compared to hundreds of markers on a legacy platform. It reinforces a thesis central to our value proposition: measuring the right proteins with sufficient sensitivity and precision can outperform larger, less targeted assays. A scalable noninvasive method to categorize co-pathology has the potential to make clinical trials more productive and precision medicine more achievable. Turning to Slide 15. As I mentioned at the start of the call, the opportunity ahead of us is massive. We serve the research market today, which is substantial on its own and estimate to reach $9 billion over the next decade. But proteomics is broadly applicable across disease areas, and we believe our platform has the potential to expand beyond research into clinical diagnostics and enable early detection and health monitoring at population scale. The real value lies in the combination of our multiplex capability and the sensitivity required for clinical use. We plan to partner with companies that brings disease domain expertise, established clinical development infrastructure, regulatory experience, reimbursement pathways and commercial channels. Think of our platform as the iPhone. We provide the hardware and the operating system, and we enable third parties to build the applications. In our case, those applications are differentiated diagnostic tests that our partners would develop and where applicable, seek regulatory marketing authorization. To realize this opportunity, we are developing a clinical instrument, ARGO HT/DX, and are executing a phased diagnostic enablement strategy as outlined on Slide 16. The first step is obtaining FDA marketing authorization to establish that our platform meets the regulatory bar for clinical use. We believe this will drive adoption for use in late-phase clinical trials and open the door for partners to develop laboratory directed tests and IVD tests on our platform. We also believe that pursuing FDA marketing authorization may drive increased use in RUO space across discovery, translation and clinical trial, because we offer something most research tools cannot: a clear path to clinical translation. Once we obtain FDA marketing authorization, the second step is developing high-value differentiated test offerings. With authorization in hand, we plan to partner with IVD and LDT companies to support the development of tests, whether stand-alone or as part of a multi-omics solutions that are meaningfully differentiated from what exists today. Before I hand the call over to Justin to discuss our financial results, I want to take a moment to acknowledge the passing of our Board member, Ian Ratcliffe. Ian brought Alamar the same quality that defined his entire career: intellectual rigor, genuine care for the people around him and unwavering belief in the power of scientific innovation to reach patients and change lives. His commitment to Alamar and to the broader scientific community was a hallmark of his leadership, and we're better for having had him in our corner. We are at an extraordinary moment for proteomics, and I believe Alamar is uniquely positioned to lead it. I'm deeply proud of what this team has built and energized by what lies ahead. With that, I will turn the call over to Justin. Justin McAnear: Thanks, Yuling. This is our first earnings call as a public company following the completion of our IPO in April. It is a meaningful milestone, and I am proud of the team's execution on both the financial and operational fronts. With that, I will now walk through our second quarter 2026 financial results in more detail. Unless otherwise noted, all growth rates reflect year-over-year comparisons. We plan to update the installed base and average instrument pull-through metrics on an annual basis, and we'll be sharing those on our year-end 2026 earnings call. Starting on Slide 17. Total revenue for the second quarter was $29.4 million, up 82% compared to $16.2 million in the second quarter of 2025. These results reflect rapid and broad-based adoption of our ARGO HT platform across our customer segments and geographies. Consumables continued to be the standout performer and accounted for more than half of the total revenue in the second quarter. Consumables revenue was $15.5 million, up 147% year-over-year, driven by strong demand for our multiplex panel kits as our installed base has scaled. Instrument revenue in the second quarter was $7.8 million, up 35%, driven by continued growth in new instrument placements. We are pleased with the pace of placements. And as Yuling noted, the installed base now supports a strong and growing recurring consumables revenue stream. Service and other revenue was $6.2 million in the quarter, up 49%. This line is composed of our Technology Access Program, or TAP, services and maintenance contracts. Today, the majority of our service revenue is TAP revenue. Revenue from maintenance contracts is a smaller fraction as a large portion of our installed base is still covered by the 1-year warranty. As a reminder, TAP serves 3 key objectives: driving new customer acquisition, supporting custom assay development and beta testing new products prior to launch. It is worth noting that TAP is not intended to be a long-term service business. Our goal is for new customers to ultimately purchase their own instrument or transfer their work to a CRO, and we actively manage our TAP program with that conversion in mind. The increase in Q2 was driven primarily by larger custom assay development projects. As our platform continues to gain adoption and our publication base grows, we expect TAP services to grow at a slower rate than other areas of the business. Looking at the geographic breakdown for the second quarter on Slide 18, the Americas represented 69% of revenue, EMEA represented 22% and APAC represented 9%. We are actively building out our international presence, and we see meaningful runway in both EMEA and APAC as we deepen our distribution partnerships and direct commercial efforts in those regions. From a customer mix perspective, 52% of second quarter revenue came from academic and research institutions, 42% from biopharmaceutical companies and the remaining 6% from distributors. The continued strength in biopharma is particularly encouraging, as these customers tend to run larger, more sustained cohort studies that drive meaningful consumables pull-through over time. Gross profit for the second quarter was $17.7 million compared to $8.6 million in the prior year period. Gross margin was 60% in the second quarter of 2026, up from 53% in the second quarter of 2025. Gross margins were at an all-time high. The improvement was primarily driven by 2 factors: first, manufacturing efficiencies as consumable production has scaled significantly; and second, a favorable shift in product mix with a greater proportion of revenue coming from consumables, which carry higher gross margins than instruments. Total operating expenses in the second quarter were $31.2 million compared to $16.5 million in the prior year period. These increases primarily reflect deliberate investments in the people, infrastructure and R&D capabilities. Research and development expenses were $13.8 million in the quarter, up 55% from $8.9 million a year earlier. The increase reflects higher lab supply costs to support our expanding consumable panel menu and an increase in personnel costs. Selling, general and administrative expenses were $17.4 million in the quarter, up 129% from $7.6 million in the prior year period. This was primarily driven by an increase in personnel costs as well as higher professional services costs for legal and accounting services. Loss from operations was $13.5 million in the second quarter compared to $7.9 million in the second quarter of 2025. This includes $3.3 million of stock-based compensation for the second quarter of 2026 as compared to $0.7 million for the second quarter of 2025. Net loss was $13.2 million in the second quarter compared to $7 million in Q2 2025. We ended the second quarter in a strong financial position. As of June 30, 2026, we had $256.3 million in cash, cash equivalents, short-term investments and restricted cash. Also, this month, we refinanced our existing debt facility with SVB First Citizens Bank into a new, more flexible revolving credit facility at improved terms and more favorable pricing. This facility includes $60 million available at closing, along with an additional $40 million uncommitted accordion for a total of $100 million. We're pleased to continue to deepen our relationship with SVB First Citizens Bank, who has been a valuable partner in supporting our growth since well before our IPO. The strength of our balance sheet reflects our April IPO, which generated net proceeds of $197.8 million. We are well capitalized to execute our plan, and we intend to deploy this capital strategically to scale our organization and capabilities in support of future growth by expanding our commercial sales and support function, increasing manufacturing capacity and enhancing our research and development organization to expand product content. Turning to our outlook for the rest of the year. We expect revenue for full year 2026 to be in the range of $116 million to $120 million, reflecting expected annual growth of 59% at the midpoint of the range. For the third quarter, we expect our revenue to be a modest sequential increase from Q2. On the expense side, we expect to continue investing in headcount across the commercial and R&D functions, along with the ongoing cost of operating as a public company. And as we grow, we remain focused on maintaining a disciplined path towards profitability. With that, I will turn the call back to Yuling. Yuling Luo: Thanks, Justin. Before we open to questions, I want to acknowledge the Alamar team. The work required to build this business, complete an IPO and deliver a quarter like this simultaneously is extraordinary. I'm deeply grateful for everyone on the team who made it possible. Looking forward to the rest of 2026, we have 3 major goals. First, growing our installed base by at least 100 instruments for the full year 2026, strengthening the foundation for recurring consumable revenue. Second, maintaining per instrument pull-through above $400,000, which we believe is the clearest signal our customers are running our platform at real scale. And third, advancing into additional large cohort studies, particularly in translational and biopharma settings where demand for high-sensitivity multiplex protein data is most acute. Into 2027, the milestone gets more significant. We plan to continue to grow our installed base of instruments and launching a multiplex panel targeting a new disease area, submit the ARGO HT/DX for FDA marketing authorization and establish partnerships to drive our clinical and diagnostic enablement strategy. Our conviction in this opportunity has never been stronger. We are well capitalized. We have a clear road map, and we have a team that has demonstrated it can execute. With that, we'll now open the call for questions. Operator? Operator: [Operator Instructions] We have a question from the line of Casey Woodring with JPMorgan. Casey Woodring: Congrats on the quarter, guys. Maybe to start, I wanted to ask just on demand trends between academic and pharma customers in the quarter. I know pharma has been driving growth for you guys of late. So just curious if that was the case again, if you could frame up the growth by that customer segment. And then I would also be curious to hear if you saw any underlying improvement in the academic markets. And then just as a follow-up, on the instruments you placed in 2Q, more broadly speaking, I was just curious if you could give us a sense if growth was driven by more placements into existing accounts or with new customers. Yuling Luo: Yes. Thank you, Casey, for the questions. In Q2, we have seen strong growth from both academics as well as biopharma segment. And we have seen exceptional adoption by our neuro. I think that's one of the reasons we're seeing incredibly strong growth in the academic market. Going forward, we continue to expect significant growth on both academic as well as research market. Justin McAnear: Casey, to answer the second part of your question on instrument placements, you asked if we're mostly going to new customers or existing customers. So if we look at this year-to-date, the majority of instrument placements are going to new customers. Yuling Luo: Maybe just to add that, I think we're excited to see the existing customer continue to adopt additional instrument. To me, this is a good indication of existing customers have found a lot of value and the utility of our platform. And they like to expand and some expansion are beyond one site to additional site, which is quite exciting to see. Operator: And our next question is from Dan Brennan with TD Cowen. Daniel Brennan: Congrats on the first quarter. Maybe just the first one on the quarter itself on the TAP strength and maybe kind of unpacking a little bit consumables and instruments. So TAP drove like really strong growth, some upside. Could you just unpack, was there any onetime nature in that at all? Do you expect, kind of, TAP to continue? And then I know, Justin, you talked about modest growth sequentially. Just wondering, is that typical? Or is that being conservative? Just anything on that front as well. And then I have a follow-up. Yuling Luo: Dan, thanks for the questions. So we're very pleased with our consumable pull-through and growth almost 150% over last year at the same time. We're also quite excited to see the TAP increase, which is certainly significantly above what we have anticipated. And one of the major reasons for this is the custom assay development. We are happy to see that the custom assay development indicates the customer wants to move from discovery, leveraging our platform to translation and future clinical application. So we do believe that over the longer term, those increase in customer revenues will translate into future consumables or instrument adoptions. Justin McAnear: Thanks. And Dan, to add to that about the TAP program, like we said, it's got 3 objectives: drive new customers, support the custom assay development and then beta testing of new products ahead of launch. We do have a really strong TAP pipeline. And as Yuling said, we believe it's a good leading indicator of future demand. Now to your question around onetime, I suppose you could say if we're -- ideally, all of TAP would be onetime because then we would be transitioning to new products. We did see a higher volume for TAP in this past quarter than we had been expecting. I do expect that the trend will continue in the near term into Q3, but not at the level that we saw in -- not at the level that we saw in Q2. And then you had another question around just a step-up overall from Q2 to Q3 when we talk about a modest step-up. And so when we use the term modest, to me, that means, like, low single-digit sequential growth from Q2 to Q3. Operator: It comes from Puneet Souda with Leerink. Puneet Souda: First one is on pull-through. I wanted to understand the 400,000 pull-through number that you have and you expect to continue to exceed that. You exceeded that number last year, too. So just trying to understand, sort of, how are you thinking about that number longer term, the cadence of that? As I look at this quarter, was there a step down in the pull-through from Q1 to Q2? And is that just a function of more installs, which is an indicator of future consumables growth in our mind? But just also the last part of the question is, could you maybe talk about the ceiling that you can reach given the output of this platform on the pull-through side? And I have a follow-up. Yuling Luo: Thank you, Puneet. Certainly, we're seeing a great demand for consumables. And as I mentioned, the consumable have grown close to 150% over last year. We think this is still early days. When you acquire a new customer, it takes time for the new customer to ramp up, and that's exactly what you explained about the pull-throughs. We remain very confident that we'll continue to keep the pull-through above $400,000 this year, which I remind you that this is industry-leading. Justin McAnear: And I'll just add that new instrument placements will put some pressure on pull-through in the near term, just given the number of instruments that are being placed each quarter relative to the size of our installed base. And so we expect that there would be fluctuations quarter-to-quarter on the quarterly pull-through, which is why at this time, we're providing that metric on an annual basis. And Puneet, you had a second part around the pull-through ceiling. If you were to use the assumption that you would do 3 plates in a 24-hour period, 5 days a week, you could get to a ceiling of $5 million, $6 million per instrument on theoretical pull-through. Yuling Luo: Yes, I just want to add that many of the pharmas' time to result is critical to them. So they are not fully utilizing their capacity of the instrument, rather, they would rather buy a few more instruments to get the results faster. So that's another reason why the pull-through can be controlled. Operator: It comes from Dan Arias with Stifel. Daniel Arias: Just wanted to ask a question a little bit about the assay portfolio. Yuling, my assumption is that you're going to try and move folks that use the CNS 120 Panel to the Neuro 220 Panel pretty quickly. I guess I'm just curious whether when that happens, is there a validation process that needs to take place there? And does that create some -- a bit of a pause or anything to be contemplated when we just think about run rates and consumable pull-through rates as that's taking place? Yuling Luo: Yes. Thanks, Dan. Our product road map, very much like what we said during the IPO process. The first, we're going to double down on what's winning, which is launching the Neuro 220 Panels, where we launched this in March this year, and we have seen the incredible adoption since then. We also doubled down on the immune panel with the launch of the Immune 340 a couple of weeks ago. We see some early signs of adoption. We're quite excited about that. And going forward, we're going to build content to cover new disease areas. And certainly in the cardiovascular and metabolic disease area as well as oncology. So those are the sort of high-level product road map that we're going to go move forward. Daniel Arias: Okay. And then, Justin, maybe just following up on the consumables pull-through rate. If I look to last year, you did have this really big 3Q to 4Q step-up. Can you just talk to whether there were large orders in 4Q of last year as we sort of think about seasonality and trying to use last year as a guide for this year? I just -- I want to make sure that we model these things correctly in the early days without a ton of historical information to go by. Justin McAnear: Yes, Dan, thanks for the question. When we look at Q4 of 2025 and that step-up from Q3 into Q4, it was a pretty decent step-up. But we also did have some fairly larger orders for large cohort studies, 2 in particular that hit in Q4. And when we look at how we're thinking about the step-up this year from Q3 to Q4, we're still -- we still have larger cohort studies like that spread out over many quarters. But when you look back at Q4 of last year, those made outsized contributions just due to their size compared to the rest of the revenue base. Operator: Our next question comes from Michael Ryskin with Bank of America. Michael Ryskin: Congrats on the quarter. Justin, maybe I'll stick with both for you on the P&L. Maybe just first on the gross margin line. As you said, kind of, you guys hit 60%, nice margins in both products and services. Any reason that shouldn't carry forward just both in terms of your mix is not going to be that different going forward. It's going to continue to bias towards consumables, the efficiencies in some of your manufacturing processes as consumables scales up as just volume scales up, that should continue. So any reason that shouldn't be, sort of, the starting point going forward in gross margins? Just, sort of, could you give us the road map from here of where that number goes? And I've got a follow-up. Justin McAnear: Yes. Thanks for the question, Mike. So when we look at our 60% gross margin in Q2, that really reflects 2 primary drivers: that's the growing mix of consumables revenue, which has higher margins than the instruments; and then also the continued benefit of manufacturing scale and leveraging overhead. As consumables becomes -- continues to become a larger share of revenue, we expect that driver to expand the margin over time. But really, that's also dependent upon how quickly our instrument installed base grows and the mix between instruments, consumables and services. And so when we're looking at the rest of the year, although hitting 60% gross margin was a great milestone to hit, we do expect it to fluctuate in the near term. And I would expect that fluctuation to be in the neighborhood of the mid- to high 50s in the near term, but I would expect it to continue to trend upward over time. Michael Ryskin: Okay. All right. And then a follow-up is actually going to be on the OpEx side, R&D and SG&A. You guys helped manage that really well the last couple of quarters. You've successfully completed the IPO, upsized it. You've got some nice war chest there. During the process, you guys kind of constantly referred to the efficiency of your sales organization, your ability to leverage a really small organization for the revenues that you're getting. But now that you do have a little bit of this war chest, any change in how you're thinking about the next 3, 6, 12 months in terms of spending on OpEx and, sort of, where you see the opportunities, the levers you're going to toggle with that? Justin McAnear: Thanks for that follow-up, Mike. When we're talking about our capital allocation priorities, pretty clearly defined. Like, our largest investment would be in these 3 areas: expanding the commercial org focused on driving instrument placements and deepening the penetration in existing accounts. Next, scaling our manufacturing capacity, including our expanding our Fremont facility. And then third, continue to invest in R&D to develop new panels, new instruments, including the ARGO HT/DX and then new applications across different disease areas. Operator: And our last question comes from the line of Puneet Souda with Leerink. Puneet Souda: Just a follow-up. On those large-scale projects, I just wanted to clarify, cadence-wise, this is the 21,000 project, is that a different project that you had outlined earlier and versus the Alzheimer's project and the Alzheimer's Data Initiative and the Gates Ventures project. What I'm trying to really get to is how should we think about the samples and the cadence of those samples 2026 and then '27? Timothy White: Yes. Puneet, thank you for the follow-up. So these large cohort projects, as you did touch on, there are a couple of those, and they will be spread out over multiple quarters. So these studies naturally have long lead times more than our standard commercial orders. You have to manage sample logistics, institutional coordination and data infrastructure. So those all have to come together before we can complete the profiling at scale. So I think these are -- we've got the 2026 numbers contemplated in our guidance, and then the rest we'll see phased in over the first half of next year. Puneet Souda: Okay. And just wanted to clarify the 21,000 sample is the CLARiTI project, and that's different than the Alzheimer's Data Initiative? Timothy White: Yes. That's -- those are tied together. Yes. Yuling Luo: It's part of the Gates Ventures ADDI project. Timothy White: One is a subpart of the other. Operator: Ladies and gentlemen, this concludes our conference for today and Q&A session. Thank you all for participating, and you may now disconnect. Before you buy stock in Alamar Biosciences, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alamar Biosciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,511!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,960!* Now, it’s worth noting Stock Advisor’s total average return is 981% — a market-crushing outperformance compared to 216% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of August 17, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Alamar Biosciences (ALMR) Q2 2026 Earnings Call Transcript was originally published by The Motley Fool

This article first appeared on GuruFocus. Release Date: August 10, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Total revenue grew 82% year-over-year to $29.4 million, driven by exceptional consumable performance which surged 147%. Achieved a record 60% gross margin, up from 53% in the prior year, due to manufacturing efficiencies and a favorable product mix shift toward higher-margin consumables. Launched the first commercial multiplex blood-based immunoassay for eMTBR tau, a key Alzheimer's biomarker, positioning the company at the forefront of neurodegenerative disease research. Expanded strategic partnership with the Alzheimer's Disease Data Initiative and Gates Ventures to profile an additional 86,000 plasma samples, bringing the combined dataset to over 140,000 samples. Ended the quarter with a strong balance sheet of $256.3 million in cash and short-term investments, providing ample capital to execute growth plans and invest in R&D and commercial expansion. Surpassed 165 cumulative publications and preprints, with a four-fold increase in posters featuring its technology at AAIC, demonstrating growing scientific validation and adoption. Launched the NuLISA-Seq Immune 340 panel, the broadest multiplex immune profiling panel, opening a large and under-penetrated market opportunity in immunology. Maintained industry-leading instrument pull-through above $400,000, with a theoretical ceiling of $5-6 million per instrument, indicating strong customer engagement and platform utilization. Refinanced existing debt into a more flexible $100 million revolving credit facility with improved terms, enhancing financial flexibility. Provided full-year 2026 revenue guidance of $116 million to $120 million, reflecting expected annual growth of 59% at the midpoint. Net loss widened to $13.2 million in Q2 2026, up from $7 million in Q2 2025, reflecting increased operating expenses. SG&A expenses surged 129% year-over-year to $17.4 million, driven by higher personnel costs and professional services fees associated with operating as a public company. R&D expenses increased 55% to $13.8 million, reflecting higher lab supply costs and personnel expenses to support expanding panel menu and product development. The company expects gross margin to fluctuate in the mid-to-high 50s in the near term, indicating that the record 60% margin may not be sustained immediately. Q3 2026 revenue is expected to show only a modest sequential increase (low single-digit growth), suggesting a potential slowdown in momentum after a strong Q2. The Technology Access Program (TAP) revenue, which drove significant upside in Q2, is expected to grow at a slower rate going forward as the company focuses on converting customers to instrument purchases. Instrument revenue growth of 35% lagged overall revenue growth, indicating a potential shift in revenue mix that could pressure near-term margins. The company faces execution risks in its ambitious 2027 goals, including FDA marketing authorization for ArgoHTDx and establishing clinical diagnostic partnerships, which are subject to regulatory and market uncertainties. Large cohort study revenues are subject to long lead times and logistical complexities, which could cause revenue recognition to be lumpy and unpredictable across quarters. The passing of Board member Ian Radcliffe represents a loss of experienced leadership and guidance for the company. Warning! GuruFocus has detected 2 Warning Sign with ALMR. Is ALMR fairly valued? Test your thesis with our free DCF calculator. Q: Can you discuss the demand trends between academic and pharma customers in the quarter, and whether instrument placements were driven more by new or existing customers? A: Yuling Lo (CEO) noted strong growth from both academic and biopharma segments, with exceptional adoption in the neuro market driving academic growth. Justin McAneer (CFO) added that the majority of instrument placements year-to-date have been to new customers, while the CEO highlighted that existing customers are also expanding by adding additional instruments, which is a positive signal of platform value. Q: Can you unpack the strength in Technology Access Program (TAP) revenue, whether it was one-time in nature, and how we should think about the Q3 sequential growth? A: Yuling Lo (CEO) explained that the TAP increase was significantly above expectations, driven by custom assay development, which indicates customers are moving from discovery to translation and clinical applications. Justin McAneer (CFO) added that TAP has a strong pipeline and is a leading indicator of future demand, but while the trend will continue into Q3, it won't be at Q2 levels. He clarified that "modest" sequential growth from Q2 to Q3 means low single-digit growth. Q: How should we think about the $400,000 pull-through metric, its cadence, and what is the theoretical ceiling for pull-through per instrument? A: Yuling Lo (CEO) stated that consumables demand is strong, growing nearly 150% year-over-year, and the company remains confident in maintaining industry-leading pull-through above $400,000 annually. Justin McAneer (CFO) noted that new instrument placements will put near-term pressure on the metric, causing quarterly fluctuations, which is why it's reported annually. He added that the theoretical ceiling, assuming three plates per day, five days a week, could reach $5-6 million per instrument, though customers often prioritize faster turnaround over full capacity utilization. Q: Regarding the assay portfolio, will you move customers from the CNS120 panel to the Neuro220 panel, and does that require a validation process that could impact run rates? A: Yuling Lo (CEO) outlined the product roadmap, emphasizing a focus on doubling down on winning products like the Neuro220 panel, launched in March with incredible adoption, and the new Immune 340 panel. The company plans to build content for new disease areas like cardiovascular, metabolic, and oncology. The CEO did not specifically address the validation process but highlighted the strong adoption of new panels. Q: Can you explain the gross margin performance, whether the 60% level is sustainable, and what the roadmap for margins looks like? A: Justin McAneer (CFO) attributed the 60% gross margin to a favorable mix shift toward higher-margin consumables and manufacturing scale benefits. While he expects margins to fluctuate in the mid-to-high 50s in the near term due to instrument mix, he anticipates a continued upward trend over time as consumables become a larger share of revenue. Q: With the IPO proceeds, how are you thinking about OpEx spending and capital allocation over the next 3-12 months? A: Justin McAneer (CFO) outlined three primary capital allocation priorities: expanding the commercial organization to drive instrument placements and deepen account penetration, scaling manufacturing capacity including the Fremont facility, and investing in R&D for new panels, instruments like the ArgoHTDx, and applications across disease areas. Q: Can you clarify the cadence of large-scale cohort projects, specifically the 21,000-sample project, and how samples will be phased in 2026 and 2027? A: Todd White (President) explained that large cohort projects are spread over multiple quarters due to long lead times involving sample logistics, institutional coordination, and data infrastructure. The 2026 numbers are already contemplated in guidance, with the remainder phased in over the first half of 2027. He confirmed that the 21,000-sample project is part of the Gates Ventures/ADDI initiative, not a separate project. Q: Regarding the Q4 2025 step-up in consumables, were there large orders that drove that, and how should we model seasonality this year? A: Justin McAneer (CFO) acknowledged that Q4 2025 had a significant step-up driven by two large cohort study orders that made outsized contributions relative to the revenue base. While similar large orders are spread across multiple quarters this year, he cautioned against using last year's Q4 as a direct guide for seasonality. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Interested in Alamar Biosciences, Inc.? Here are five stocks we like better. Revenue surged 82% year over year to $29.4 million in Q2 2026, driven primarily by consumables revenue, which rose 147% to $15.5 million. Gross margin reached a record 60% as higher-margin consumables and manufacturing efficiencies improved the product mix. Alamar ended the quarter with $256.3 million in cash, investments and restricted cash after raising $197.8 million in net IPO proceeds, although its operating loss widened to $13.5 million amid increased research, sales and public-company expenses. Management forecast 2026 revenue of $116 million to $120 million and plans to add at least 100 instruments while expanding its neurology and immune panel offerings. Longer-term priorities include an FDA submission for the ARGO HT DX clinical instrument and additional diagnostic partnerships. Alamar Biosciences (NASDAQ:ALMR) reported second-quarter 2026 revenue of $29.4 million, up 82% from $16.2 million a year earlier, as growth in consumables, instrument placements and service revenue supported the company’s first earnings call since completing its April initial public offering. Chief Executive Officer Yuling Luo said the quarter reflected continued adoption of the company’s precision proteomics platform, which combines ultra-high sensitivity, specificity, multiplexing, dynamic range and automation. The company’s ARGO HT platform is used in research applications, with an initial focus on neurology and inflammation. → MarketBeat Week in Review – 08/03 - 08/07 “Q2 2026 was a strong quarter that reflects the momentum of our business,” Luo said. Consumable revenue represented 53% of total revenue and grew 147% year over year, while the company achieved a 60% gross margin for the first time. Chief Financial Officer Justin McAnear said consumables revenue totaled $15.5 million in the quarter, driven by demand for multiplex panel kits as the installed base expanded. Instrument revenue increased 35% to $7.8 million, while service and other revenue rose 49% to $6.2 million. → Quantum Earnings Week: Winners and Losers Are Finally Emerging Service revenue includes the company’s Technology Access Program, or TAP, as well as maintenance contracts. McAnear said TAP is intended to support customer acquisition, custom assay development and product beta testing rather than operate as a long-term service business. The Q2 increase was primarily attributable to larger custom assay development projects. During the question-and-answer session, President Tod White said TAP activity was higher than management had expected in the second quarter and should continue into the third quarter, though not at the Q2 level. He characterized the service pipeline as a potential leading indicator of future instrument and consumable demand. → Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War Geographically, the Americas accounted for 69% of second-quarter revenue, followed by Europe, the Middle East and Africa at 22% and Asia-Pacific at 9%. Academic and research institutions generated 52% of revenue, biopharmaceutical customers contributed 42%, and distributors represented the remaining 6%. Luo said both academic and biopharmaceutical customer segments experienced strong growth during the quarter. White added that most year-to-date instrument placements have gone to new customers, although existing customers have also been adding instruments and, in some cases, expanding platform use to additional sites. Gross profit increased to $17.7 million from $8.6 million a year earlier, and gross margin improved to 60% from 53%. McAnear attributed the expansion to manufacturing efficiencies as consumable production scaled and to a greater revenue contribution from consumables, which carry higher margins than instruments. White said gross margin could fluctuate in the mid-to-high 50% range in the near term, depending on the mix of instruments, consumables and services. However, he said management expects margins to trend higher over time as consumables become a larger share of revenue. Operating expenses rose to $31.2 million from $16.5 million in the prior-year quarter. Research and development expense increased 55% to $13.8 million, reflecting laboratory supply and personnel costs associated with expanding the company’s panel menu. Selling, general and administrative expense rose 129% to $17.4 million, driven by personnel and higher legal and accounting expenses associated with becoming a public company. Alamar reported a $13.5 million operating loss, compared with a $7.9 million loss a year earlier. Net loss was $13.2 million, versus $7 million in the second quarter of 2025. The company recorded $3.3 million in stock-based compensation during the quarter. As of June 30, Alamar had $256.3 million in cash equivalents, short-term investments and restricted cash. McAnear said the April IPO generated $197.8 million in net proceeds. The company also refinanced its debt facility with SVB First Citizens Bank, establishing a revolving credit facility with $60 million available at closing and a further $40 million uncommitted accordion. Alamar launched the NULISAseq Neuro 220 Panel in March and introduced a multiplex blood-based immunoassay for eMTBR-Tau in July. Luo said eMTBR-Tau is designed to measure tau tangle burden from blood samples and can be multiplexed with other neurodegeneration and neuroinflammation biomarkers. The company also launched the NULISAseq Immune 340 Panel, which measures approximately 340 immune-related proteins from a single blood sample, and introduced a dried blood spot extraction kit designed to make home-collected fingerstick samples compatible with its platform. Luo said Alamar added more than 40 publications and preprints during the quarter, bringing its cumulative total to 165. At the Alzheimer’s Association International Conference, the company counted more than 140 posters and presentations featuring NULISA technology, a fourfold increase from the prior year. The company also expanded its partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures to add profiling of 86,000 plasma samples using the Neuro 220 Panel. The expanded agreement includes a national-scale initiative involving approximately 21,000 plasma samples from 10,000 Alzheimer’s Disease Research Center participants. The combined dataset is expected to include more than 140,000 samples and be completed in 2027. Alamar forecast full-year 2026 revenue of $116 million to $120 million, representing 59% annual growth at the midpoint. Management expects third-quarter revenue to increase modestly sequentially from the second quarter, which White described as low-single-digit sequential growth. For the full year, the company aims to add at least 100 instruments to its installed base and maintain annual per-instrument pull-through above $400,000. White said quarterly pull-through can fluctuate as new instruments are placed, and the company plans to report installed-base and average pull-through metrics annually. Looking toward 2027, Alamar plans to launch a multiplex panel targeting another disease area, submit its ARGO HT DX clinical instrument for FDA marketing authorization, and establish partnerships to support diagnostic test development. The company said it intends to invest IPO proceeds in commercial expansion, manufacturing capacity and research and development. Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Alamar Biosciences Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

FREMONT, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended June 30, 2026. Recent Highlights Generated $29.4 million of total revenue for the second quarter of 2026, an increase of 82% as compared to the corresponding period of 2025 Launched the first commercial multiplexed blood-based immunoassay for eMTBR-tau, available in our NULISAseq™ Neuro 220 Panel and through our Technology Access Program, enabling scalable, non-invasive measurement of tau tangle burden Expanded strategic partnership with the Alzheimer's Disease Data Initiative and Gates Ventures to deliver a combined dataset of more than 140,000 samples Launched the NULISAseq™ Immune 340 Panel, our broadest multiplexed immune profiling solution for translational research and drug development Providing full-year 2026 revenue guidance of $116 million to $120 million, representing growth of 59% at the midpoint of the range as compared to 2025 "We delivered a strong second quarter with consumable revenue growing nearly 150% year-over-year," said Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences. "With the recent launches of eMTBR-tau and the Immune 340 Panel strengthening our content menu and extending into new disease areas, we believe we are well-positioned to sustain momentum into the coming quarters." Second Quarter 2026 Financial Results Revenue was $29.4 million for the second quarter of 2026, an 82% increase from $16.2 million for the corresponding prior-year period. Instrument revenue grew 35% to $7.8 million, from $5.8 million for the corresponding prior-year period, driven primarily by continued growth in new instrument placements. Consumable revenue grew 147% to $15.5 million, from $6.3 million for the corresponding prior-year period, driven primarily by strong demand for multiplex panels. Services and other revenue grew 49% to $6.2 million, from $4.1 million for the corresponding prior-year period. Gross margin was 60% for the second quarter of 2026, as compared to 53% for the corresponding prior-year period. The increase in gross margin was primarily driven by manufacturing efficiencies for consumables and a favorable shift in mix toward high-margin consumables. Operating expenses were $31.2 million for the second quarter of 2026, an 89% increase from $16.5 million for the corresponding prior-year period. The year-over-year increase in operating expenses was primarily related to planned investments in headcount, infrastructure and R&D capabilities as well as incremental public company costs. Operating loss was $13.5 million for the second quarter of 2026, as compared to an operating loss of $7.9 million for the corresponding prior-year period. This includes $3.3 million of stock-based compensation for the second quarter of 2026, as compared to $0.7 million for the second quarter of 2025. Net loss was $13.2 million for the second quarter of 2026 and higher than the $7.0 million net loss in the corresponding prior-year period. Cash, cash equivalents, short-term investments and restricted cash were $256.3 million as of June 30, 2026. 2026 Guidance Alamar Biosciences expects full year 2026 revenue to be in the range of $116 million to $120 million, representing growth of 59% at the midpoint of the range compared to full year 2025. Webcast Information Alamar Biosciences will host a conference call to discuss the second quarter 2026 financial results after market close on Monday, August 10, 2026 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at https://investors.alamarbio.com/. About Alamar Biosciences, Inc. Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO™ HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com. Forward Looking Statements This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alamar Biosciences’ estimates for the full year 2026, its financial outlook, future plans and prospects, its ability to accelerate adoption of its platform and establish a new gold standard in protein detection and analysis, its anticipated sustained momentum in revenue growth from the recent launches of eMTBR-tau and the Immune 340 Panel, and Alamar Biosciences’ ability to grow its business. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property and other risks and uncertainties described in Alamar Biosciences’ filings with the Securities and Exchange Commission (SEC), including those described from time to time under the caption “Risk Factors” and elsewhere in Alamar Biosciences’ filings with the SEC, including its Quarterly Report on Form 10-Q filed with the SEC on May 8, 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Investor contact: [email protected] Media contact: [email protected] (1)   The following table represents revenue by source for the periods indicated: (2)   Includes stock-based compensation expense as follows:

FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026. Recent Highlights Generated $26.0 million of total revenue for the first quarter of 2026, an increase of 99% as compared to the corresponding period of 2025. Launched two new products, NULISAseq™ Neuro 220 Panel and NULISAqpcr™ AD 5-plex Assay, furthering our leadership in neurodegenerative disease research. Raised approximately $220 million in gross proceeds from our initial public offering in April 2026. "We began 2026 with a record quarter, nearly doubling revenue year over year as our NULISA platform gained rapid global traction among leading academic research and biopharma customers," said Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences. "With our balance sheet significantly strengthened by the proceeds of our recent IPO, we are well-positioned to accelerate adoption of our Precision Proteomics platform and establish a new gold standard in protein detection and analysis." First Quarter 2026 Financial Results Revenue was $26.0 million for the first quarter of 2026, a 99% increase from $13.1 million for the corresponding prior-year period. Instrument revenue grew 78% to $7.4 million, from $4.1 million for the corresponding prior-year period, driven primarily by an increase in instrument placements. Consumable revenue grew 178% to $14.0 million, from $5.0 million for the corresponding prior-year period, driven primarily by pull-through tied to the larger instrument installed base as well as by a slight increase in the average selling price of our consumables. Services and other revenue grew 20% to $4.7 million, from $3.9 million for the corresponding prior-year period. Gross margin was 56% for the first quarter of 2026, as compared to 49% for the corresponding prior-year period. The increase in gross margin was primarily driven by manufacturing efficiencies realized through larger consumables production volumes, higher average selling prices across both instruments and consumables, and by a favorable shift in product mix toward higher-margin consumables. Operating expenses were $26.8 million for the first quarter of 2026, a 79% increase from $14.9 million for the corresponding prior-year period. The year-over-year increase in operating expenses was primarily related to increased personnel costs, increased costs related to expansion of our product offerings, and increased professional costs for legal and accounting services. Operating loss was $12.3 million for the first quarter of 2026, as compared to an operating loss of $8.6 million for the corresponding prior-year period. This includes $1.5 million of stock-based compensation for the first quarter of 2026, as compared to $0.6 million for the first quarter of 2025. Net loss was $21.3 million for the first quarter of 2026, including a loss of $8.6 million related to the remeasurement of convertible notes, and higher than the $7.7 million net loss in the corresponding prior-year period. Cash, cash equivalents, and restricted cash were $69.5 million as of March 31, 2026. Recent Developments In April, after quarter end, Alamar Biosciences completed its initial public offering, raising $197.8 million of net proceeds, after deducting underwriter commissions, discounts and other expenses incurred by the company. The company intends to provide full-year 2026 revenue guidance in conjunction with its second quarter 2026 earnings release in August 2026. About Alamar Biosciences, Inc. Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO™ HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Forward Looking Statements This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Alamar Biosciences’ future plans and prospects, its ability to accelerate adoption of its platform and establish a new gold standard in protein detection and analysis, anticipated timing and content regarding full-year 2026 guidance, and Alamar Biosciences’ ability to grow its business. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property and other risks and uncertainties described in Alamar Biosciences’ filings with the Securities and Exchange Commission (SEC), including those described from time to time under the caption “Risk Factors” and elsewhere in Alamar Biosciences’ filings with the SEC, including its prospectus filed with the SEC pursuant to Rule 424(b)(4), dated April 16, 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Investor contact: [email protected] Media contact: [email protected] (1) The following table represents revenue by source for the periods indicated: (2) Includes stock-based compensation expense as follows: